Get the Stockscreener App
86.47
1.00%
0.86
After Hours:
86.47
Apogee Therapeutics Inc stock is traded at $86.47, with a volume of 970.52K.
It is up +1.00% in the last 24 hours and up +11.12% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$85.61
Open:
$85.41
24h Volume:
970.52K
Relative Volume:
0.97
Market Cap:
$6.45B
Revenue:
-
Net Income/Loss:
$-255.84M
P/E Ratio:
-20.52
EPS:
-4.2149
Net Cash Flow:
$-232.60M
1W Performance:
-4.89%
1M Performance:
+11.12%
6M Performance:
+53.78%
1Y Performance:
+134.65%
1-Day Range:
$84.08
$88.45
1-Week Range:
$84.08
$92.55
52-Week Range:
$34.34
$95.31
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
86.47 | 6.39B | 0 | -255.84M | -232.60M | -4.2149 |
VRTX
Vertex Pharmaceuticals Inc
|
426.01 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
744.44 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
783.74 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.51 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.90 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
APGE stock up as skin disease drug shows sustained 52-week efficacy - MSN
Apogee Therapeutics Stock Surges as Investors Bet on Immunology Breakthrough - HarianBasis.co
Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters - Yahoo Finance
Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis - msn.com
Apogee Therapeutics prices upsized $350M offering at $70 a share - MSN
How Apogee Therapeutics Inc. (APGE) Affects Rotational Strategy Timing - Stock Traders Daily
Apogee Therapeutics, Inc. ($APGE) CEO 2025 Pay Revealed - Quiver Quantitative
Apogee Therapeutics Announces Upcoming Board Resignations, Governance Shift - TipRanks
Apogee Therapeutics (APGE) 2026 meeting to vote on directors, pay and auditor - Stock Titan
Two directors resign from Apogee Therapeutics (NASDAQ: APGE) board, shrinking it to seven - Stock Titan
Certain Common Stock of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026. - marketscreener.com
Certain Pre-Funded Warrants of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026. - marketscreener.com
Certain Restricted Stock Units of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026. - marketscreener.com
Apogee Thera (APGE) Stock Price Target | Q4 2025: Earnings Beat EstimatesTrending Volume Leaders - Cổng thông tin điện tử Tỉnh Sơn La
APGE (Apogee Therapeutics Inc.) posts narrower Q4 2025 loss than estimates, shares rise modestly after its latest quarterly earnings release.GDR - Cổng thông tin điện tử tỉnh Tây Ninh
APGE (Apogee Therapeutics Inc.) Q4 2025 EPS outpaces forecasts, shares gain as investors reward narrower than expected loss.Social Flow Trades - UBND thành phố Hải Phòng
APGE Earnings History & Surprises | EPS & Revenue Results | APOGEE THERAPEUTICS INC (NASDAQ:APGE) - ChartMill
Apogee Therapeutics (APGE) CEO exercises options, holds 1.14M shares - Stock Titan
Apogee Therapeutics stock hits all-time high at 92.48 USD By Investing.com - Investing.com India
Insider Sell: Jane Henderson Sells 2,000 Shares of Apogee Therap - GuruFocus
Apogee Therapeutics CFO Henderson sells $180,000 in stock - Investing.com
Apogee Therapeutics CFO Henderson sells $180,000 in stock By Investing.com - Investing.com India
Apogee Therapeutics (APGE) CFO sells 2,000 shares under 10b5-1 plan - Stock Titan
Apogee Therapeutics stock hits all-time high at 92.48 USD - Investing.com
Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year HighStill a Buy? - MarketBeat
(APGE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Apogee Therapeutics Insider Sold Shares Worth $1,651,664, According to a Recent SEC Filing - Moomoo
How Investors May Respond To Apogee Therapeutics (APGE) CEO Share Sale and US$403 Million Equity Raise - Sahm
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aug PreEarnings: Will Apogee Therapeutics Inc benefit from seasonalityPortfolio Return Report & Expert Approved Trade Ideas - baoquankhu1.vn
Dow Update: Should value investors consider Apogee Therapeutics IncQuarterly Market Summary & Accurate Technical Buy Alerts - baoquankhu1.vn
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) CEO Sells 20,000 Shares of Stock - MarketBeat
Apogee Therapeutics CEO Henderson sells $1.65 million in stock By Investing.com - Investing.com Australia
Apogee Therapeutics CEO Henderson sells $1.65 million in stock - Investing.com
Apogee Therapeutics (APGE) CEO sells 20,000 shares under Rule 10b5-1 plan - Stock Titan
Aberdeen Group plc Lowers Stake in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):